Invention Grant
- Patent Title: Molecules with specificity for CD79 and CD22
-
Application No.: US16513002Application Date: 2019-07-16
-
Publication No.: US11261252B2Publication Date: 2022-03-01
- Inventor: Helene Margaret Finney , Stephen Edward Rapecki , Michael John Wright , Kerry Louise Tyson
- Applicant: UCB BIOPHARMA SRL
- Applicant Address: BE Brussels
- Assignee: UCB BIOPHARMA SRL
- Current Assignee: UCB BIOPHARMA SRL
- Current Assignee Address: BE Brussels
- Agency: Medler Ferro Woodhouse & Mills PLLC
- Priority: GB1412658 20140716
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/18 ; A61K39/00
Abstract:
The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.
Public/Granted literature
- US20200024346A1 MOLECULES WITH SPECIFICITY FOR CD79 AND CD22 Public/Granted day:2020-01-23
Information query
